Adagio(US:IVVD) ZACKS·2025-11-06 15:16Core Insights - Invivyd, Inc. reported a quarterly loss of $0.06 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.05, marking a 20% earnings surprise [1] - The company's revenues for the quarter ended September 2025 were $13.13 million, missing the Zacks Consensus Estimate by 18.96%, compared to $9.3 million in the same quarter last year [2] - Invivyd's stock has increased approximately 243% since the beginning of the year, significantly outperforming the S&P 500's gain of 15.6% [3] Financial Performance - Over the last four quarters, Invivyd has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $19.3 million, and for the current fiscal year, it is -$0.43 on revenues of $58.6 million [7] Industry Context - Invivyd operates within the Zacks Medical - Biomedical and Genetics industry, which is currently ranked in the top 41% of over 250 Zacks industries [8] - The performance of stocks in this industry is influenced by the overall industry outlook, with top-ranked industries historically outperforming lower-ranked ones by a factor of more than 2 to 1 [8] Future Outlook - The sustainability of Invivyd's stock price movement will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The estimate revisions trend for Invivyd was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]